SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M. D. Sanchez-Nino, A. Ortiz, 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians, Nephrology Dialysis Transplantation, 2015, 30, 3, 394

    CrossRef

  2. 2
    P. Watson, A. Brennan, H. Birch, H. Fang, M. Petri, An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort, Rheumatology, 2015, 54, 4, 623

    CrossRef

  3. 3
    Sharan K Rai, Jinoos Yazdany, Paul R Fortin, J Antonio Aviña-Zubieta, Approaches for estimating minimal clinically important differences in systemic lupus erythematosus, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  4. 4
    Natasha Jordan, David P D’Cruz, Belimumab for the treatment of systemic lupus erythematosus, Expert Review of Clinical Immunology, 2015, 11, 2, 195

    CrossRef

  5. 5
    Daniel J. Wallace, Belimumab: Where Are We Three Years After FDA Approval?, Current Treatment Options in Rheumatology, 2015, 1, 1, 42

    CrossRef

  6. 6
    Christine B. Bernal, Leonid D. Zamora, Sandra V. Navarra, Biologic therapies in systemic lupus erythematosus, International Journal of Rheumatic Diseases, 2015, 18, 2
  7. 7
    Thomas Karonitsch, Martin Aringer, Biologika bei SLE, Wiener Medizinische Wochenschrift, 2015, 165, 1-2, 40

    CrossRef

  8. 8
    Jamal Mikdashi, Ola Nived, Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  9. 9
    Alexis Mathian, Miguel Hie, Fleur Cohen-Aubart, Zahir Amoura, Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects, Drugs, 2015, 75, 8, 835

    CrossRef

  10. 10
    Daniel J. Wallace, The evolution of drug discovery in systemic lupus erythematosus, Nature Reviews Rheumatology, 2015,

    CrossRef

  11. 11
    Ignasi Rodriguez-Pintó, Gerard Espinosa, Ricard Cervera, Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus, Clinical Investigation, 2015, 5, 6, 561

    CrossRef

  12. 12
    Vijay Rao, Caroline Gordon, Advances in the assessment of lupus disease activity and damage, Current Opinion in Rheumatology, 2014, 26, 5, 510

    CrossRef

  13. 13
    R. Furie, M. A. Petri, V. Strand, D. D. Gladman, Z. J. Zhong, W. W. Freimuth, Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, Lupus Science & Medicine, 2014, 1, 1, e000031

    CrossRef

  14. 14
    M.-S. Doutre, Des scores d’évolutivité dans le lupus, oui mais…, Annales de Dermatologie et de Vénéréologie, 2014, 141, 10, 571

    CrossRef

  15. 15
    Yu Guo, Amr H. Sawalha, Qianjin Lu, Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application, Clinical Immunology, 2014, 155, 1, 79

    CrossRef

  16. 16
    V. Strand, R. A. Levy, R. Cervera, M. A. Petri, H. Birch, W. W. Freimuth, Z. J. Zhong, A. E. Clarke, Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials, Annals of the Rheumatic Diseases, 2014, 73, 5, 838

    CrossRef

  17. 17
    Laura Runkel, Jennifer Stacey, Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?, Expert Opinion on Biological Therapy, 2014, 14, 4, 491

    CrossRef

  18. 18
    Raphaèle Seror, Elke Theander, Hendrika Bootsma, Simon J. Bowman, Athanasios Tzioufas, Jacques-Eric Gottenberg, Manel Ramos-Casals, Thomas Dörner, Philippe Ravaud, Xavier Mariette, Claudio Vitali, Outcome measures for primary Sjögren's syndrome: A comprehensive review, Journal of Autoimmunity, 2014, 51, 51

    CrossRef

  19. 19
    Anca D. Askanase, Jinoos Yazdany, Charles T. Molta, Post-marketing Experiences with Belimumab in the Treatment of SLE Patients, Rheumatic Disease Clinics of North America, 2014, 40, 3, 507

    CrossRef

  20. 20
    Xiao-juan Zhu, Yan Shi, Feng Zhang, Qing-min Yao, Yan-xia Liu, Ning-ning Shan, Dan Wang, Jun Peng, Jian Xu, Ming Hou, Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia, British Journal of Haematology, 2014, 166, 5
  21. 21
    Fabien B. Vincent, Eric F. Morand, Pascal Schneider, Fabienne Mackay, The BAFF/APRIL system in SLE pathogenesis, Nature Reviews Rheumatology, 2014, 10, 6, 365

    CrossRef

  22. 22
    Morton A Scheinberg, Dinesh Srinivasan, Renee S Martin, The potential role of blisibimod for the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 2014, 9, 2, 121

    CrossRef

  23. 23
    Thomas D. Szucs, Daniele Puri, Patricia R. Blank, The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus, European Journal of Clinical Pharmacology, 2014, 70, 8, 983

    CrossRef

  24. 24
    William Stohl, Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus, Expert Opinion on Therapeutic Targets, 2014, 18, 4, 473

    CrossRef

  25. 25
    Jacob A. S. Vorstman, Will Spooren, Antonio M. Persico, David A. Collier, Stefan Aigner, Ravi Jagasia, Jeffrey C. Glennon, Jan K. Buitelaar, Using genetic findings in autism for the development of new pharmaceutical compounds, Psychopharmacology, 2014, 231, 6, 1063

    CrossRef

  26. 26
    R. Mina, M. S. Klein-Gitelman, S. Nelson, B. A. Eberhard, G. Higgins, N. G. Singer, K. Onel, L. Tucker, K. M. O'Neil, M. Punaro, D. M. Levy, K. Haines, A. Martini, N. Ruperto, D. Lovell, H. I. Brunner, Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus, Annals of the Rheumatic Diseases, 2014, 73, 2, 401

    CrossRef

  27. 27
    A. Thanou, E. Chakravarty, J. A. James, J. T. Merrill, Which outcome measures in SLE clinical trials best reflect medical judgment?, Lupus Science & Medicine, 2014, 1, 1, e000005

    CrossRef

  28. 28
    Anna Nuttall, David A. Isenberg, Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects, Best Practice & Research Clinical Rheumatology, 2013, 27, 3, 309

    CrossRef

  29. 29
    Philip R. Harvey, Caroline Gordon, B-Cell Targeted Therapies in Systemic Lupus Erythematosus, BioDrugs, 2013, 27, 2, 85

    CrossRef

  30. 30
    Bevra Hannahs Hahn, Belimumab for Systemic Lupus Erythematosus, New England Journal of Medicine, 2013, 368, 16, 1528

    CrossRef

  31. 31
    Moncef Zouali, Eugene A. Uy, Belimumab Therapy in Systemic Lupus Erythematosus, BioDrugs, 2013, 27, 3, 225

    CrossRef

  32. You have free access to this content32
    Preeta K. Chugh, Bhupinder S. Kalra, Belimumab: targeted therapy for lupus, International Journal of Rheumatic Diseases, 2013, 16, 1
  33. 33
    Joan T. Merrill, Co-stimulatory molecules as targets for treatment of lupus, Clinical Immunology, 2013, 148, 3, 369

    CrossRef

  34. 34
    R. Fischer-Betz, M. Schneider, Empfehlungen zum Einsatz von Belimumab beim systemischen Lupus erythematodes, Zeitschrift für Rheumatologie, 2013, 72, 5, 462

    CrossRef

  35. 35
    Toru Igarashi, Tsutomu Igarashi, Akira Shimizu, Yasuhiko Itoh, Intravenous Cyclophosphamide Pulse Therapy in Japanese Children with Systemic Lupus Erythematosus, Journal of Nippon Medical School, 2013, 80, 5, 396

    CrossRef

  36. 36
    Hui Jen Ding, Caroline Gordon, New biologic therapy for systemic lupus erythematosus, Current Opinion in Pharmacology, 2013, 13, 3, 405

    CrossRef

  37. 37
    Natasha Jordan, Pamela MK Lutalo, David P D’Cruz, Novel therapeutic agents in clinical development for systemic lupus erythematosus, BMC Medicine, 2013, 11, 1, 120

    CrossRef

  38. 38
    Zahi Touma, Murray B. Urowitz, Dafna D. Gladman, Outcome measures in systemic lupus erythematosus, Indian Journal of Rheumatology, 2013, 8, S46

    CrossRef

  39. 39
    Ju-Yang Jung, Chang-Bum Bae, Chang-Hee Suh, Promising biomarkers for systemic lupus erythematosus, Expert Opinion on Medical Diagnostics, 2013, 7, 6, 601

    CrossRef

  40. 40
    Zahi Touma, Murray B Urowitz, Dafna D Gladman, Systemic lupus erythematosus: an update on current pharmacotherapy and future directions, Expert Opinion on Biological Therapy, 2013, 13, 5, 723

    CrossRef

  41. 41
    Antonio La Cava, Targeting the BLyS-APRIL signaling pathway in SLE, Clinical Immunology, 2013, 148, 3, 322

    CrossRef

  42. 42
    Daniel J. Wallace, Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus, Current Rheumatology Reports, 2013, 15, 7

    CrossRef

  43. 43
    Aikaterini Thanou, Joan T. Merrill, Top 10 Things to Know About Lupus Activity Measures, Current Rheumatology Reports, 2013, 15, 6

    CrossRef

  44. 44
    Aikaterini Thanou, Joan T. Merrill, Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys, Nature Reviews Rheumatology, 2013, 10, 1, 23

    CrossRef

  45. 45
    Tobias Brummaier, Erich Pohanka, Andrea Studnicka-Benke, Herwig Pieringer, Using cyclophosphamide in inflammatory rheumatic diseases, European Journal of Internal Medicine, 2013, 24, 7, 590

    CrossRef

  46. 46
    Raphaëlle Seror, Lupus érythémateux, 2013,

    CrossRef

  47. 47
    George Bertsias, Antonios Fanouriakis, Dimitrios T. Boumpas, Kelley's Textbook of Rheumatology, 2013,

    CrossRef

  48. 48
    Ronald F. van Vollenhoven, Dubois' Lupus Erythematosus and Related Syndromes, 2013,

    CrossRef

  49. 49
    Zahi Touma, Dafna D. Gladman, Murray B. Urowitz, Dubois' Lupus Erythematosus and Related Syndromes, 2013,

    CrossRef

  50. 50
    Chang-Hee Suh, B Cell Targeted Therapy in Rheumatic Disease, Journal of Rheumatic Diseases, 2012, 19, 2, 67

    CrossRef

  51. 51
    Alexis Boneparth, Anne Davidson, B-cell activating factor targeted therapy and lupus, Arthritis Research & Therapy, 2012, 14, Suppl 4, S2

    CrossRef

  52. 52
    Géraldine Falgarone, Robin Dhote, Marie-Christophe Boissier, B-cell targeted treatments for lupus: The journey counts as much as the destination, Joint Bone Spine, 2012, 79, 5, 437

    CrossRef

  53. 53
    Kirsten Fairfax, Ian R. Mackay, Fabienne Mackay, BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus, IUBMB Life, 2012, 64, 7
  54. 54
    Pamela M K Lutalo, David P D'Cruz, Belimumab for the management of systemic lupus erythematosus, Expert Opinion on Biological Therapy, 2012, 12, 7, 957

    CrossRef

  55. 55
    Diane Lewis Horowitz, Richard Furie, Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?, Current Rheumatology Reports, 2012, 14, 4, 318

    CrossRef

  56. You have free access to this content56
    William Stohl, Falk Hiepe, Kevin M. Latinis, Mathew Thomas, Morton A. Scheinberg, Ann Clarke, Cynthia Aranow, Frank R. Wellborne, Carlos Abud-Mendoza, Douglas R. Hough, Lilia Pineda, Thi-Sau Migone, Z. John Zhong, William W. Freimuth, W. Winn Chatham, Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 2012, 64, 7
  57. 57
    G J Dennis, Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus, Clinical Pharmacology & Therapeutics, 2012, 91, 1
  58. 58
    Eric G. Boyce, Bryan E. Fusco, Belimumab: Review of Use in Systemic Lupus Erythematosus, Clinical Therapeutics, 2012, 34, 5, 1006

    CrossRef

  59. 59
    William Stohl, Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?, Current Rheumatology Reports, 2012, 14, 4, 303

    CrossRef

  60. 60
    Géraldine Falgarone, Robin Dhote, Marie-Christophe Boissier, Biothérapies anti-B du lupus : le chemin compte autant que le but, Revue du Rhumatisme, 2012, 79, 4, 297

    CrossRef

  61. 61
    Mollie N. Carruthers, John H. Stone, Vikram Deshpande, Arezou Khosroshahi, Development of an IgG4-RD Responder Index, International Journal of Rheumatology, 2012, 2012, 1

    CrossRef

  62. 62
    Laurent Arnaud, Alexis Mathian, Jacques Boddaert, Zahir Amoura, Late-Onset Systemic Lupus Erythematosus, Drugs & Aging, 2012, 29, 3, 181

    CrossRef

  63. 63
    E. M. A. Ball, A. L. Bell, Lupus arthritis--do we have a clinically useful classification?, Rheumatology, 2012, 51, 5, 771

    CrossRef

  64. 64
    William Stohl, Recent therapeutic advances in the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 2012, 7, 3, 257

    CrossRef

  65. 65
    Z. Touma, M. B. Urowitz, S. Taghavi-Zadeh, D. Ibanez, D. D. Gladman, Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months, Rheumatology, 2012, 51, 10, 1814

    CrossRef

  66. 66
    C.-S. Yee, C. Gordon, D. A. Isenberg, B. Griffiths, L.-S. Teh, I. N. Bruce, Y. Ahmad, A. Rahman, A. Prabu, M. Akil, N. McHugh, C. Edwards, D. D'Cruz, M. A. Khamashta, V. T. Farewell, The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally, Rheumatology, 2012, 51, 11, 2099

    CrossRef

  67. 67
    William Stohl, David M Hilbert, The discovery and development of belimumab: the anti-BLyS–lupus connection, Nature Biotechnology, 2012, 30, 1, 69

    CrossRef

  68. 68
    K.M.A.C. Luijten, J. Tekstra, J.W.J. Bijlsma, M. Bijl, The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment, Autoimmunity Reviews, 2012, 11, 5, 326

    CrossRef

  69. 69
    Aisha Lateef, Michelle Petri, Unmet medical needs in systemic lupus erythematosus, Arthritis Research & Therapy, 2012, 14, Suppl 4, S4

    CrossRef

  70. 70
    Ricard Cervera, Gerard Espinosa, Immunotherapeutic Agents for SLE, 2012,

    CrossRef

  71. 71
    Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace, Dana Tegzová, Jorge Sanchez-Guerrero, Andreas Schwarting, Joan T. Merrill, W. Winn Chatham, William Stohl, Ellen M. Ginzler, Douglas R. Hough, Z. John Zhong, William Freimuth, Ronald F. van Vollenhoven, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 2011, 63, 12
  72. 72
    Andrew C. Chan, B cell immunotherapy in autoimmunity – 2010 update, Molecular Immunology, 2011, 48, 11, 1344

    CrossRef

  73. 73
    Eliana Mariño, Pablo A. Silveira, Jessica Stolp, Shane T. Grey, B cell-directed therapies in type 1 diabetes, Trends in Immunology, 2011, 32, 6, 287

    CrossRef

  74. 74
    Antonis Fanouriakis, Dimitrios T Boumpas, George K Bertsias, Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus, Expert Review of Clinical Pharmacology, 2011, 4, 4, 437

    CrossRef

  75. 75
    Celeste B. Burness, Paul L. McCormack, Belimumab, Drugs, 2011, 71, 18, 2435

    CrossRef

  76. 76
    Laurent Chiche, Noémie Jourde, Julien Mancini, Belimumab for systemic lupus erythematosus, The Lancet, 2011, 377, 9783, 2080

    CrossRef

  77. 77
    Changhai Ding, Ran Li, Jianhua Xu, Flavia Cicuttini, Graeme Jones, Belimumab therapy for systemic lupus erythematosus and potential treatment of rheumatoid arthritis, Drug Development Research, 2011, 72, 7
  78. 78
    John H Stone, BLISS! Lupus learns its lessons, The Lancet, 2011, 377, 9767, 693

    CrossRef

  79. 79
    Ricard Cervera, Gerard Espinosa, Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus, Clinical Investigation, 2011, 1, 11, 1555

    CrossRef

  80. 80
    Michelle PETRI, Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice, International Journal of Rheumatic Diseases, 2011, 14, 1
  81. 81
    Noam Jacob, William Stohl, Cytokine disturbances in systemic lupus erythematosus, Arthritis Research & Therapy, 2011, 13, 4, 228

    CrossRef

  82. 82
    Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León, Coman Tanasescu, Eugeny Nasonov, Joung-Liang Lan, Lilia Pineda, Z John Zhong, William Freimuth, Michelle A Petri, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, The Lancet, 2011, 377, 9767, 721

    CrossRef

  83. 83
    Dennis Cada, Terri Levien, Danial Baker, Formulary Drug Reviews - Belimumab, Hospital Pharmacy, 2011, 46, 7, 519

    CrossRef

  84. 84
    Landmark lupus approval opens door for next wave of drugs, Nature Reviews Drug Discovery, 2011, 10, 4, 243

    CrossRef

  85. 85
    Juanita Romero-Diaz, David Isenberg, Rosalind Ramsey-Goldman, Measures of adult systemic lupus erythematosus: Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), Arthritis Care & Research, 2011, 63, S11
  86. 86
    Vibeke Strand, Alvina D Chu, Measuring outcomes in systemic lupus erythematosus clinical trials, Expert Review of Pharmacoeconomics & Outcomes Research, 2011, 11, 4, 455

    CrossRef

  87. 87
    Christoph Fiehn, Research Highlights, Immunotherapy, 2011, 3, 11, 1293

    CrossRef

  88. 88
    William Stohl, Jean L Scholz, Michael P Cancro, Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside, Current Opinion in Rheumatology, 2011, 23, 3, 305

    CrossRef

  89. 89
    Teresa Otón, Lucía Silva Fernández, Mónica Fernández Castro, José Luis Andreu, Terapia biológica dirigida contra los linfocitos B en el lupus eritematoso sistémico, Seminarios de la Fundación Española de Reumatología, 2011, 12, 1, 10

    CrossRef

  90. 90
    C.-S. Yee, V. T. Farewell, D. A. Isenberg, B. Griffiths, L.-S. Teh, I. N. Bruce, Y. Ahmad, A. Rahman, A. Prabu, M. Akil, N. McHugh, C. Edwards, D. D'Cruz, M. A. Khamashta, C. Gordon, The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients, Rheumatology, 2011, 50, 5, 982

    CrossRef

  91. 91
    Kenneth C. Kalunian, Joan T. Merrill, Systemic Lupus Erythematosus, 2011,

    CrossRef

  92. 92
    Joan T. Merrill, Kenneth C. Kalunian, Jill P. Buyon, Systemic Lupus Erythematosus, 2011,

    CrossRef

  93. 93
    Noam Jacob, William Stohl, Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future, Autoimmunity, 2010, 43, 1, 84

    CrossRef

  94. 94
    R. John Looney, B Cell-Targeted Therapies for Systemic Lupus Erythematosus, Drugs, 2010, 70, 5, 529

    CrossRef

  95. 95
    Michael J. Townsend, John G. Monroe, Andrew C. Chan, B-cell targeted therapies in human autoimmune diseases: an updated perspective, Immunological Reviews, 2010, 237, 1
  96. 96
    Aisha Lateef, Michelle Petri, Biologics in the treatment of systemic lupus erythematosus, Current Opinion in Rheumatology, 2010, 22, 5, 504

    CrossRef

  97. 97
    I. N. Bruce, C. Gordon, J. T. Merrill, D. Isenberg, Clinical trials in lupus: what have we learned so far?, Rheumatology, 2010, 49, 6, 1025

    CrossRef

  98. 98
    William Stohl, Noam Jacob, Shunhua Guo, Laurence Morel, Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus–like autoimmunity, Arthritis & Rheumatism, 2010, 62, 8
  99. 99
    Lars Rönnblom, Keith B. Elkon, Cytokines as therapeutic targets in SLE, Nature Reviews Rheumatology, 2010, 6, 6, 339

    CrossRef

  100. 100
    Jose L. Marenco, Antonio Fernández-Nebro, Experiencia con rituximab en el tratamiento de pacientes con lupus. La base de datos LESIMAB, Reumatología Clínica, 2010, 6, 28

    CrossRef

  101. 101
    Paul A. Monach, Global versus organ-specific outcome measures in systemic lupus erythematosus: Comment on the articles by Furie et al, Nikpour et al, Wallace et al, Burgos et al, and Ramos-Casals et al, Arthritis Care & Research, 2010, 62, 4
  102. 102
    L. Arnaud, Z. Amoura, Lupus systémique et biothérapies: mise au point en 2010, La Revue de Médecine Interne, 2010, 31, S296

    CrossRef

  103. 103
    Meenakshi Jolly, Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus, Current Rheumatology Reports, 2010, 12, 4, 229

    CrossRef

  104. 104
    Jijie Gu, Tariq Ghayur, Rationale and development of multispecific antibody drugs, Expert Review of Clinical Pharmacology, 2010, 3, 4, 491

    CrossRef

  105. 105
    Ian N Bruce, Re-evaluation of biologic therapies in systemic lupus erythematosus, Current Opinion in Rheumatology, 2010, 22, 3, 273

    CrossRef

  106. 106
    Anne Davidson, Targeting BAFF in autoimmunity, Current Opinion in Immunology, 2010, 22, 6, 732

    CrossRef

  107. 107
    J. Pope, The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations, Rheumatology, 2010, 49, 9, 1616

    CrossRef

  108. 108
    Daniel J. Wallace, William Stohl, Richard A. Furie, Jeffrey R. Lisse, James D. McKay, Joan T. Merrill, Michelle A. Petri, Ellen M. Ginzler, W. Winn Chatham, W. Joseph McCune, Vivian Fernandez, Marc R. Chevrier, Z. John Zhong, William W. Freimuth, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus, Arthritis Care & Research, 2009, 61, 9
  109. 109
    Penelope Ward, Mark Bodmer, Antibodies in Phase III Studies for Immunological Disorders,
  110. 110
    Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, David P. D'Cruz, Belimumab (Benlysta®),
  111. 111
    Jasvinder A Singh, Shahrzad Noorbaloochi, Matthew D Tucker, Belimumab for systemic lupus erythematosus, The Cochrane Library,